Feng Gege, Wang Jianhong, Jiang Yujie, Li Ying, Ding Mei, Wang Na, Wang Xin
Department of Hematology, Provincial Hospital Affiliated to Shandong University, Ji'nan 250021, China.
Zhonghua Xue Ye Xue Za Zhi. 2014 Aug;35(8):743-6. doi: 10.3760/cma.j.issn.0253-2727.2014.08.017.
To compare the validity of three currently used chronic myeloid leukemia (CML) scoring systems (Sokal CML prognostic scoring system, Hasford prognostic scoring system, and EUTOS prognostic scoring system) in chronic phase CML (CP-CML) patients.
One hundred and thirteen CP-CML patients taking hydroxyurea, interferon or imatinib were enrolled in this study. All patients were stratified into different groups according to each scoring system and different therapies respectively. And overall survival (OS) rates were observed and compared among different groups.
Three scoring systems were effective predictors of OS in CP-CML patients, and EUTOS scoring system may predict more validly. Hasford scoring system was well correlated with Sokal and EUTOS scores (r=0.792, P<0.01 and r=0.624, Plt;0.01). The correlation between Sokal and EUTOS scores was relatively weak (r=0.508, Plt;0.01). Despite imatinib's marked effect in prolonging survival of CML patients, it was incapable of prolonging survival in Sokal, Hasford and EUTOS high- risk patients.
EUTOS prognostic scoring system may predict better than Sokal and Hasford systems in CML patients. Classification of patients based on the three scoring systems may assist in the choice of appropriate therapy for CML.
比较三种目前使用的慢性髓性白血病（CML）评分系统（索卡尔CML预后评分系统、哈斯福德预后评分系统和EUTOS预后评分系统）在慢性期CML（CP-CML）患者中的有效性。
113例服用羟基脲、干扰素或伊马替尼的CP-CML患者纳入本研究。所有患者分别根据每种评分系统和不同治疗方法分层为不同组。观察并比较不同组的总生存率（OS）。
三种评分系统都是CP-CML患者OS的有效预测指标，且EUTOS评分系统可能预测得更有效。哈斯福德评分系统与索卡尔和EUTOS评分相关性良好（r=0.792，P<0.01和r=0.624，P<0.01）。索卡尔和EUTOS评分之间的相关性相对较弱（r=0.508，P<0.01）。尽管伊马替尼在延长CML患者生存期方面有显著效果，但它无法延长索卡尔、哈斯福德和EUTOS高危患者的生存期。
在CML患者中，EUTOS预后评分系统可能比索卡尔和哈斯福德系统预测得更好。基于这三种评分系统对患者进行分类可能有助于为CML选择合适的治疗方法。
